Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Change in Acquisitions & Divestments (2016 - 2026)

Tandem Diabetes Care filings provide 12 years of Change in Acquisitions & Divestments readings, the most recent being $56.5 million for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 16.23% to $56.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $257.1 million, a 16.12% decrease, with the full-year FY2025 number at $257.1 million, down 16.12% from a year prior.
  • Change in Acquisitions & Divestments hit $56.5 million in Q4 2025 for Tandem Diabetes Care, up from $54.1 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $546.7 million in Q4 2021 to a low of -$285.3 million in Q3 2021.
  • Median Change in Acquisitions & Divestments over the past 5 years was $115.5 million (2022), compared with a mean of $112.5 million.
  • The widest YoY moves for Change in Acquisitions & Divestments: up 3940.48% in 2021, down 698.38% in 2021.
  • Tandem Diabetes Care's Change in Acquisitions & Divestments stood at $546.7 million in 2021, then tumbled by 73.19% to $146.6 million in 2022, then decreased by 10.81% to $130.7 million in 2023, then tumbled by 48.42% to $67.4 million in 2024, then fell by 16.23% to $56.5 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $56.5 million (Q4 2025), $54.1 million (Q3 2025), and $81.4 million (Q2 2025) per Business Quant data.